Kunming, China – 20 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center publicized a batch of drug attribute changes on the provincial procurement platform, reclassifying five products from non‑essential‑drug status to essential drug (including former provincial‑supplement items) under the National Essential Medicines List (2026 Edition) and the Yunnan Provincial Supplemental Drug Catalog. Affected manufacturers must complete notification‑and‑commitment filing with the Yunnan Provincial Medical Products Administration (MPA) effective immediately, while objections must be lodged within five working days of the publicity date.
Policy Snapshot
| Item | Detail |
|---|---|
| Agency | Yunnan Provincial Government Procurement and Transfer Center |
| Document | Publicity of Drug Attribute Changes for Platform‑Traded Products (annexed Attribute Change Table) |
| Basis | National Essential Medicines List (2026 Edition); Yunnan Provincial Supplemental Drug Catalog |
| Products Affected | 5 – all reclassified from non‑essential drug to essential drug / former provincial supplement |
| Price & Registration Impact | Approval numbers unchanged; procurement price ceilings unchanged |
| Filing Obligation | Notification‑and‑commitment filing with Yunnan MPA, effective from the publicity date |
| Objection Window | 5 working days from publicity (enterprises: 0871‑63606934, Drug & Device Procurement Section; public: 0871‑65330065, Comprehensive Supervision Section) |
| Filing Venue | Reception Hall, 1F, Yunnan Institute for Food and Drug Control and Testing – New Building, 616 Kefa Road, Kunming; Tel: 0871‑63112057 |
Products Reclassified
| Product ID | Generic Name | Dosage Form | Specification | Manufacturer / Bidder | New Attribute |
|---|---|---|---|---|---|
| 53521224 | Cefradine for Injection | Injection | 1.0 g (as C16H19N3O4S) | Shaanxi Dunsi Pharmaceutical Co., Ltd. | Former provincial supplement |
| 53527176 | Inosine Injection | Injection | 2 ml : 0.1 g | Shaanxi Dunsi Pharmaceutical Co., Ltd. / Xi’an Tangchen Pharmaceutical Co., Ltd. (bidder) | Former provincial supplement |
| 53526685 | Pancreatin Enteric‑Coated Tablets | Enteric‑coated tablet | 0.3 g × 24 tablets/box | Chongqing Tianzhi Pharmaceutical Co., Ltd. | Essential drug (NEML 2026) |
| 53825865 | Pancreatin Enteric‑Coated Tablets | Enteric‑coated tablet | 0.3 g × 48 tablets/box | Chongqing Tianzhi Pharmaceutical Co., Ltd. | Essential drug (NEML 2026) |
| 53501920 | Longbishu Tablets | Sugar‑coated tablet | 0.3 g core weight × 18 tablets/box | Qinhuangdao Da’en Pharmaceutical Co., Ltd. | Essential drug (NEML 2026) |
Compliance Obligations & Procedure
- Notification‑and‑Commitment Filing: For products flagged “essential drug (incl. former provincial supplement)”, the filing process opens immediately. Enterprises must follow the requirements set out in the Yunnan MPA’s published announcement (mpa.yn.gov.cn, notice t20210917_1231876) and complete commitment‑based filing in person, bringing a printed copy of this publicity notice to the designated Yunnan MPA location.
- Consequences of Non‑Filing: Enterprises that fail to complete the notification‑and‑commitment filing bear full responsibility for the consequences, per the notice – a clear signal that platform trading status may hinge on timely compliance.
- Dual‑Track Objection Mechanism: Applicant enterprises with queries on the publicized information contact the Center’s Drug & Device Procurement Section (0871‑63606934); other enterprises or members of the public raising objections contact the Comprehensive Supervision Section (0871‑65330065) – both within five working days of the publicity date, with the publicized content open to general supervision.
- Administrative Continuity: Because drug approval numbers and procurement price ceilings remain unchanged, the reclassification is an attribute‑level adjustment rather than a repricing event – preserving existing commercial terms while altering catalog status.
Market Impact & Outlook
- NEML 2026 Alignment: Three of the five products (both Pancreatin SKUs and Longbishu Tablets) were upgraded directly under the National Essential Medicines List (2026 Edition), illustrating how provinces are synchronizing procurement‑platform attributes with the refreshed national catalog.
- Essential‑Drug Advantage: Essential‑drug designation typically carries policy preference in procurement and clinical use at public medical institutions – a status upgrade that can broaden access for the affected manufacturers’ products in Yunnan.
- Provincial‑Supplement Track: The two former provincial‑supplement items (Cefradine for Injection, Inosine Injection) reflect continued recognition of Yunnan’s supplemental catalog alongside the national list, per the notice’s stated basis.
- Tight Compliance Clock: With filing open “effective immediately” and only five working days to lodge objections, manufacturers must act within the same week to secure catalog status and avoid jeopardizing platform trading eligibility.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding filing outcomes, objection handling, catalog status, and platform trading eligibility for the five reclassified drug products in Yunnan Province. Actual results may differ due to risks including filing completion status, objection decisions, and subsequent policy adjustments by the Yunnan Provincial Government Procurement and Transfer Center and the Yunnan Provincial Medical Products Administration.-China Health Reform Pulse
Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27877&CatalogId=3